Classic congenital adrenal hyperplasia, more commonly called classic CAH, is when there is an enzyme missing in the adrenal gland, which causes the body to have the inability to make enough cortisol.

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for the rare disorder that works by directly targeting the underlying ...

Diseases associated with excess ACTH can ... Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. For more information about the ...

Adults with primary aldosteronism had improvements in disease severity after undergoing ... factor type 1 receptor to treat congenital adrenal hyperplasia, according to a press release.

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.